Excerpt
On March 24, 2020, a 1-day public workshop titled The Role of Digital Health Technologies in Drug Development was convened by the National Academies of Sciences, Engineering, and Medicine. This workshop builds on prior efforts to explore how virtual clinical trials facilitated by digital health technologies (DHTs) might change the landscape of drug development. To explore the challenges and opportunities in using DHTs for improving the probability of success in drug R&D, enabling better patient care, and improving precision medicine, the workshop featured presentations and panel discussions on the integration of DHTs across all phases of drug development. Throughout the workshop, participants considered how DHTs could be applied to achieve the greatest impact—and perhaps even change the face of how clinical trials are conducted—in ways that are also ethical, equitable, safe, and effective. This publication summarizes the presentations and discussions from the workshop.
Copyright 2020 by the National Academy of Sciences. All rights reserved.
Grants and funding
This activity was supported by contracts between the National Academy of Sciences and 23andMe; AbbVie Inc.; American Academy of Nursing; American College of Medical Genetics and Genomics; American Medical Association; Amgen Inc. (Contract No. GHCCOPS-CSARF-175837); Association for Molecular Pathology; Association of American Medical Colleges; AstraZeneca; Biogen; Blue Cross Blue Shield Association; Burroughs Wellcome Fund (Contract No. 1020264); College of American Pathologists; Color Genomics; Critical Path Institute; Department of Health and Human Services (Contract No. 75A50120C00006): Health Resources and Services Administration (Contract No. HHSH250201500001I; Task Order No. HHSH25034003T); Eisai Inc.; Eli Lilly and Company (Contract No. 4900709231); FasterCures–Milken Institute; Foundation for the National Institutes of Health; Friends of Cancer Research; Geisinger; Genome Medical Holding Company; Genosity; GlaxoSmithKline (Contract No. OTH-PPL-32245); Helix; Illumina; The Jackson Laboratory; Janssen Research & Development, LLC (Contract No. C2020004715); Johnson & Johnson; Kaiser Permanente; Merck & Co., Inc. (MRLCPO-19-5290 and MRLCPO-10-106723); Myriad Women's Health; National Institutes of Health (Contract No. HHSN263201800029I; Task Order Nos. HHSN26300007 and HHSN26300010): All of Us Research Program, National Cancer Institute, National Center for Advancing Translational Sciences, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, National Institute on Aging, Office of Disease Prevention, Office of Extramural Research, Office of Science Policy; National Society of Genetic Counselors; New England Journal of Medicine; Pfizer Inc.; Regeneron Pharmaceuticals; Sanofi (Contract No. 4472309 and Contract No. 57505685); Takeda Pharmaceuticals (Contract No. 53108); The University of Vermont Health Network Medical Group; U.S. Air Force Medical Service (Contract No. FA8052-17-P-0007); U.S. Food and Drug Administration (Grant No. 5R13FD005496-04 and Grant No. 5R13FD005496-05); and Vibrent Health. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.